Effect of @entity8673 on @entity177 in XXXX with moderate @entity740 and cardiovascular disease.

@entity1 @entity644 @entity8 @entity740 @entity177 @entity5017 @entity2453 @entity583 @entity8673 @entity165
Limited data suggest that @entity2453 reductase inhibitors (statins) may slow @entity177 in individuals with @entity740 . This study was conducted to determine whether @entity8673 reduced rates of @entity177 in @entity1 with moderate @entity740 . This was a post hoc subgroup analysis of a randomized double-blind placebo controlled trial. Data were analyzed from the CARE study (a randomized trial of @entity8673 versus placebo in 4159 @entity1 with previous @entity583 and total plasma @entity165 < 240 mg/dl). @entity1 with estimated @entity5017 ( @entity5017 ) < 60 ml/min per 1.73 m(2) body surface area at baseline were considered to have moderate @entity740 . Multivariate regression was used to calculate rates of decline in @entity5017 for individuals receiving @entity8673 and placebo, controlling for prospectively determined covariates that might influence rates of renal function loss. Change in renal function could be calculated in 3384 individuals, of whom 690 (20.4%) had @entity5017 < 60 ml/min per 1.73 m(2) and were eligible for inclusion. Among all individuals with @entity5017 < 60 ml/min per 1.73 m(2)), the @entity5017 decline in the @entity8673 group was not significantly different from that in the placebo group (0.1 ml/min per 1.73 m(2)/yr slower; 95% CI, -0.2 to 0.4; P = 0.49). However, there was a significant stepwise inverse relation between @entity5017 before treatment and slowing of renal function loss with @entity8673 use, with more benefit in those with lower @entity5017 at baseline (P = 0.04). Rate of change in @entity5017 in the @entity8673 group was 0.6 ml/min per 1.73 m(2)/yr slower than placebo (95% CI, -0.1 to 1.2; P = 0.07) in those with @entity5017 < 50 ml/min, and 2.5 ml/min per 1.73 m(2)/yr slower (95% CI, 1.4 to 3.6 slower; P = 0.0001) in those with @entity5017 < 40 ml/min per 1.73 m(2)/yr. @entity8673 also reduced rates of @entity8 to a greater extent in @entity1 with than without @entity644 at baseline (P = 0.006). It is concluded that @entity8673 may @entity177 in individuals with moderate to severe @entity8 , especially those with @entity644 . These findings require confirmation by a large randomized trial conducted specifically in @entity1 with @entity740 .
